View ValuationSunBioInc 将来の成長Future 基準チェック /06現在、 SunBioIncの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長24.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 10SunBio,Inc., Annual General Meeting, Mar 24, 2026SunBio,Inc., Annual General Meeting, Mar 24, 2026, at 11:00 Tokyo Standard Time. Location: conference room, 129, eunbong-ro, namdong-gu, incheon South Koreaお知らせ • Mar 25SunBio,Inc. (KOSDAQ:A067370) announces an Equity Buyback for 160,513 shares, for KRW 1,000 million.SunBio,Inc. (KOSDAQ:A067370) announces a share repurchase program. Under the program, the company will repurchase up to 160, 513 shares, for KRW 1,000 million pursuant to a trust contract with Korea Investment & Securities. The shares will be repurchased at a price of KRW 6,230 per share. The purpose of the share repurchase program is to stabilize the share price and to enhance shareholder value. The share repurchase program is valid until September 25, 2025. As of March 23, 2025, the company had 8,222 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.お知らせ • Mar 07SunBio,Inc., Annual General Meeting, Mar 31, 2025SunBio,Inc., Annual General Meeting, Mar 31, 2025, at 10:30 Tokyo Standard Time. Location: conference room, 129, eunbong-ro, namdong-gu, incheon South KoreaUpcoming Dividend • Dec 20Upcoming dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 11 April 2025. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (0.5%).New Risk • Nov 01New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.2% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2014 fiscal period end). High level of non-cash earnings (95% accrual ratio). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩77.9b market cap, or US$56.6m).お知らせ • Sep 04SunBio,Inc. announced that it expects to receive KRW 5 billion in funding from Samsung Securities Co.,Ltd., NH Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd. and another investorSunBio,Inc. announced a private placement to issue Zero Coupon Series 4 Bearer-Type Interest-Free Unsecured Private Placement Convertible Bonds due September 5, 2029 for the gross proceeds of KRW 5,000,000,000 on September 3, 2024. The transaction will include participation from new investors Synergy IB Win-Win Innovation New Technology Investment Fund KRW 2,500,000,000,Samsung Securities Co., Ltd. (in the fiduciary position of Fund 1) KRW 1,200,000,000, NH Investment & Securities Co., Ltd . (in the fiduciary position of Fund 2) KRW 800,000,000 and Mirae Asset Securities Co., Ltd. (in the fiduciary position of Fund 3) KRW 500,000,000. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on September 5, 2024. The bonds are 100% convertible into 676,315 shares at a fixed conversion price of KRW 7,393 from September 5, 2025 to August 5, 2029. The bonds bear zero coupon and maturity rate and matures on September 5, 2029.お知らせ • Mar 10SunBio,Inc., Annual General Meeting, Mar 29, 2021SunBio,Inc., Annual General Meeting, Mar 29, 2021, at 11:00 Korea Standard Time.Is New 90 Day High Low • Feb 15New 90-day high: ₩22,000The company is up 140% from its price of ₩9,167 on 17 November 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.Is New 90 Day High Low • Dec 16New 90-day high: ₩17,950The company is up 2.0% from its price of ₩17,650 on 17 September 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period.Is New 90 Day High Low • Nov 19New 90-day low: ₩13,450The company is down 4.0% from its price of ₩13,950 on 21 August 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、SunBioInc は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A067370 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20142,1711,394-868-824N/Aアナリストによる今後の成長予測収入対貯蓄率: A067370の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A067370の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A067370の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A067370の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A067370の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A067370の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/14 13:22終値2026/06/12 00:00収益2014/12/31年間収益2014/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SunBio,Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 10SunBio,Inc., Annual General Meeting, Mar 24, 2026SunBio,Inc., Annual General Meeting, Mar 24, 2026, at 11:00 Tokyo Standard Time. Location: conference room, 129, eunbong-ro, namdong-gu, incheon South Korea
お知らせ • Mar 25SunBio,Inc. (KOSDAQ:A067370) announces an Equity Buyback for 160,513 shares, for KRW 1,000 million.SunBio,Inc. (KOSDAQ:A067370) announces a share repurchase program. Under the program, the company will repurchase up to 160, 513 shares, for KRW 1,000 million pursuant to a trust contract with Korea Investment & Securities. The shares will be repurchased at a price of KRW 6,230 per share. The purpose of the share repurchase program is to stabilize the share price and to enhance shareholder value. The share repurchase program is valid until September 25, 2025. As of March 23, 2025, the company had 8,222 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.
お知らせ • Mar 07SunBio,Inc., Annual General Meeting, Mar 31, 2025SunBio,Inc., Annual General Meeting, Mar 31, 2025, at 10:30 Tokyo Standard Time. Location: conference room, 129, eunbong-ro, namdong-gu, incheon South Korea
Upcoming Dividend • Dec 20Upcoming dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 11 April 2025. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (0.5%).
New Risk • Nov 01New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.2% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2014 fiscal period end). High level of non-cash earnings (95% accrual ratio). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩77.9b market cap, or US$56.6m).
お知らせ • Sep 04SunBio,Inc. announced that it expects to receive KRW 5 billion in funding from Samsung Securities Co.,Ltd., NH Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd. and another investorSunBio,Inc. announced a private placement to issue Zero Coupon Series 4 Bearer-Type Interest-Free Unsecured Private Placement Convertible Bonds due September 5, 2029 for the gross proceeds of KRW 5,000,000,000 on September 3, 2024. The transaction will include participation from new investors Synergy IB Win-Win Innovation New Technology Investment Fund KRW 2,500,000,000,Samsung Securities Co., Ltd. (in the fiduciary position of Fund 1) KRW 1,200,000,000, NH Investment & Securities Co., Ltd . (in the fiduciary position of Fund 2) KRW 800,000,000 and Mirae Asset Securities Co., Ltd. (in the fiduciary position of Fund 3) KRW 500,000,000. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on September 5, 2024. The bonds are 100% convertible into 676,315 shares at a fixed conversion price of KRW 7,393 from September 5, 2025 to August 5, 2029. The bonds bear zero coupon and maturity rate and matures on September 5, 2029.
お知らせ • Mar 10SunBio,Inc., Annual General Meeting, Mar 29, 2021SunBio,Inc., Annual General Meeting, Mar 29, 2021, at 11:00 Korea Standard Time.
Is New 90 Day High Low • Feb 15New 90-day high: ₩22,000The company is up 140% from its price of ₩9,167 on 17 November 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Dec 16New 90-day high: ₩17,950The company is up 2.0% from its price of ₩17,650 on 17 September 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period.
Is New 90 Day High Low • Nov 19New 90-day low: ₩13,450The company is down 4.0% from its price of ₩13,950 on 21 August 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.